Olanzapine Treatment of Patients With Bipolar I Disorder

Status Completed

Clinical Trial Summary

The purpose of this study is to assess whether olanzapine is superior to placebo in patients with bipolar depression.

Clinical Trial Description

1. Dose range and administration mode: Oral Olanzapine 5mg - 20mg/day

2. Duration:

1. Screening phase is 2-28 days.

2. Double-blind treatment phase is 6 weeks

3. Open-label extension phase is 18 weeks ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00510146
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 3
Start date	August 2007
Completion date	July 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04469322` - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression	N/A
Not yet recruiting	`NCT05958940` - BioClock: Bright Light Therapy for Depressive Disorders	N/A
Recruiting	`NCT02919280` - Dallas 2K: A Natural History Study of Depression
Completed	`NCT00060489` - Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression	Phase 3
Recruiting	`NCT05767073` - LIVES: Personalized Lifestyle Intervention for Patients With Depression	N/A
Completed	`NCT04121091` - Pramipexole to Target "Anhedonic Depression"	Phase 2
Recruiting	`NCT04057378` - Optimal Electrical Stimulus During Electroconvulsive Therapy	Phase 4
Completed	`NCT03287037` - The Effects of tDCS on Depressive Symptoms,Neurocognitive Function and HRV in Unipolar Depression and Bipolar Depression	N/A
Completed	`NCT00483548` - Adjunctive Ziprasidone in the Treatment of Bipolar I Depression	Phase 3
Not yet recruiting	`NCT05568823` - Biomarkers of ANTidepressant RESponse and Development Risk of Bipolar Disorder	N/A
Completed	`NCT00191399` - Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response	Phase 4
Recruiting	`NCT05436613` - Transcranial Direct Current Stimulation Therapy for Bipolar Depression	N/A
Completed	`NCT03538275` - Chronobiology and Depression: Circadian Analytics as a Biomarker for Depressive Subtypes
Recruiting	`NCT04846010` - Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2	Phase 1/Phase 2
Withdrawn	`NCT02625779` - Combined Cytidine and Creatine-containing Drug in the Treatment of the Bipolar Depression	Phase 2
Not yet recruiting	`NCT06462196` - Natural History of Depression, Bipolar Disorder and Suicide Risk
Recruiting	`NCT02778256` - Study of the Effectiveness of Vestibular Stimulation Treatment in the Depressive Phase of Bipolar Disorder	N/A
Active, not recruiting	`NCT04643210` - Management of my Bipolarity Intervention in Bipolar Disorder Patients	N/A
Completed	`NCT01396447` - Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression	Phase 2
Enrolling by invitation	`NCT02827045` - Study of a Vestibular Biomarker of Phase in Bipolar Disorder